Inovio Pharmaceuticals to Implement Pilgrim Quality Solutions in the Cloud

Pilgrim Quality Solutions announced that Inovio Pharmaceuticals has selected Pilgrim to support its quality automation initiatives at its manufacturing and administrative sites and distribution centers.

Inovio will implement Pilgrim’s SmartSolve QMS platform as its single source for Quality Compliance management, replacing previous disparate and manual systems and increasing visibility and reporting of quality processes, particularly for audits and internal control, across the enterprise. It will deploy the integrated SmartSolve solutions in the Pilgrim Cloud.

“As an innovative and growing life science company, Inovio was seeking an intuitive, automated quality management system that provides instant access to accurate data, has built-in best practices and capabilities, and can handle the needs of both its Clinical and Manufacturing groups,” said Richard Lowrey, Pilgrim’s Chief Executive Officer. “SmartSolve meets each of those criteria, and its pre-built and validation-ready cloud solution is configurable, flexible, and scalable enough to match Inovio’s rate of growth.”

With the implementation of SmartSolve’s core management solutions, Inovio will establish a common system for both its clinical and post-clinical QMS needs. Initially, SmartSolve will support Inovio’s quality and facilitate its compliance in the key areas of Document Control, Training Management, Nonconformance Management, Corrective & Preventive Action, Change Control, and Audit Management. Additionally, SmartSolve Quality Intelligence will enable Inovio to analyze the quality system data it extracts from each of the integrated solutions.

“Our integrated quality and compliance management solutions will help Inovio Pharmaceuticals cost-effectively establish and manage critical processes and best practices throughout the entire enterprise, and support compliance with ISO and other regulatory standards,” Lowrey said. “Going forward, we look forward to being a strategic business provider for Inovio and watching it grow as a vanguard in the immunotherapies arena,” he said.

Leave A Reply

Your email address will not be published.